echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > A well-known pharmaceutical company has sold its holding subsidiary with an annual revenue of more than 10 billion yuan

    A well-known pharmaceutical company has sold its holding subsidiary with an annual revenue of more than 10 billion yuan

    • Last Update: 2019-12-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [industry trends of pharmaceutical network] on December 17, Tianshili announced that the company signed a framework agreement with Chongqing pharmaceutical yesterday, agreeing to sell the equity of its holding subsidiary Tianjin Tianshili pharmaceutical marketing group (hereinafter referred to as "Tianshili marketing") According to the framework agreement, Chongqing pharmaceutical intends to purchase 87.47% of the shares of Tianshi marketing directly and indirectly held by the company and the shares of Tianshi marketing held by other shareholders of Tianshi marketing by paying cash consideration In addition, Chongqing pharmaceutical will also purchase 100% equity of Shaanxi Tianshili Pharmaceutical Logistics Co., Ltd held by Tianshili holding According to the data, Tianshi marketing is located in the pharmaceutical circulation industry, mainly responsible for the original pharmaceutical business segment of Tianshi, mainly engaged in the distribution and distribution of drugs, medical devices, health products and other products, retail chain, chronic disease management and pharmaceutical value-added services, which are collaborative with the business of heavy Pharmaceutical Holdings On August 15, 2017, Tianshi marketing was listed on the new third board, and was allowed to make market transfer in the stock to market on April 13, 2018 However, in October this year, the company's board of directors and the general meeting of shareholders have considered and passed relevant proposals on the application for termination of listing In the first half of 2019, the distribution and distribution business of drugs and medical devices marketed by Tianshi has spread to Shaanxi, Beijing, Liaoning, Tianjin, Shandong, Hunan, Guangdong and Shanxi Meanwhile, chain drugstores have been set up in Liaoning, Tianjin, Shandong, Guangdong and other regions, with self owned drugstores as the main part and franchised drugstores as the auxiliary, and online drugstores have been set up for medical e-commerce services According to TSL's report for the first half of 2019, the operating revenue in the first half of the year increased by 11.10% over the same period of last year, the revenue of pharmaceutical industry increased by 0.62%, the revenue of pharmaceutical business increased by 17.89%, and the sales revenue of pharmaceutical business segment reached 6.07 billion yuan, accounting for 64.72% of the company's main business revenue In addition, according to the financial report data, in 2018 and the first half of 2019, the operating revenue of TISS marketing was 11.65 billion yuan and 6.5 billion yuan respectively, and the net profit was 100 million yuan and 49.99 million yuan respectively From the perspective of the profit corresponding to the revenue, the company's gross profit rate, yield, etc have been hovering at a low level, and the cash flow has been in a relatively tense state In the first half of 2019, the net cash flow generated by its business activities is - 620 million yuan, and the asset liability ratio of the consolidated basis is 85.77% The industry believes that the high asset liability ratio of the company will increase the financing cost and difficulty of the company, and the shortage of capital flow will also bring a certain debt repayment risk Shaanxi Tianshili Logistics Co., Ltd is a pharmaceutical three-party logistics company, which mainly provides three-party logistics services for the upstream and downstream of the pharmaceutical health industry supply chain It is reported that Chongqing pharmaceutical plans to effectively expand the sales area and accelerate the pace of the company's national network layout through the asset acquisition According to the data, Sinopharm holdings will focus on "strengthening internal control and promoting growth" in the future, comprehensively deepen reform, consolidate business foundation, optimize management innovation, improve service quality, and make every effort to promote the coordinated development of the three major sectors of pharmaceutical commerce, pharmaceutical research and development, and medical care and health It will take 2-3 years to realize the strategic goal of "going to the whole country", and become the fifth national pharmaceutical commercial enterprise Tianshili said that the equity transfer of the subsidiary was based on its strategic development needs, in order to further focus on the pharmaceutical industry business and enhance its core competitiveness Through the sale of assets, Tianshili will further focus on the pharmaceutical industry, continue to promote the coordinated development of modern Chinese medicine, biological medicine and chemical medicine, and build an innovative pharmaceutical R & D cluster.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.